Company profile
Edwards Lifesciences Corporation
NYSE: EW · Healthcare · Medical - Devices
#51 of 1,422 Healthcare companies by revenue57th-percentile growth
EA Score
86AFH 89DQ 93GM 58SS 93
v0.1 · 65/100 weight · provisional
↑ market scale, disclosure history · ↓ growth stability, revenue growth (YoY)
Methodology →Revenue TTM
$6.3B
Rev growth YoY (TTM)
+13.8%
Net income (FY)
$1.1B
Employees
16,000
as of 2026-08-04
Market cap
$51.1B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.1B$6.1B2025
Net income$1.1B$1.1B2025
Operating income$1.3B$1.3B2025
Total assets$13.7B$13.7B2025
Liabilities$3.4B$3.4B2025
Equity$10.3B$10.3B2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY23
FY24
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Transcatheter Heart Valves74%
Surgical Heart Valve Therapy17%
Transcatheter Mitral And Tricuspid Therapies9%
By geography
UNITED STATES58%
Europe25%
Rest of World11%
JAPAN6%
The read
What is Edwards Lifesciences Corporation’s revenue?
Edwards Lifesciences Corporation booked $6.1B in FY2025 revenue, growing 12% year over year — about the middle of the pack among Healthcare companies we track, at a 17.7% net margin.
Peers · Healthcare
Avantor, Inc.68BArdent Health Inc.61COrganon & Co.66BSTERIS plc76B+Encompass Health Corporation76B+Agilon Health, Inc.56CNeighbors
Orange →Key facts
CEOBernard J. Zovighian
SectorHealthcare
IndustryMedical - Devices
HeadquartersIrvine, CA
ExchangeNYSE: EW
Employees16,000
IPO date2000-03-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.